March 4th Week, 2025 Regulatory Events 🎯 CStone Pharmaceuticals submitted a Type II variation application to the EMA for sugemalimab (Cejelmy; anti-PD-L1) to treat stage III NSCLC patients who have not progressed following concurrent or sequential platinum-based CRT. (Ref 1) ❓ How do sugemalimab’s outcomes compare with those of previously approved AstraZeneca’s durvalumab? Special Designations ⭐ Shandong Boan Biotechnology's BA1302 (a first-in-class CD228-directed ADC) has

March 2nd Week, 2025 Mergers & Acquisitions 🤝 Checkpoint Therapeutics Inc is set to be acquired by SUN PHARMA, an Indian pharma giant. This deal will strengthen Sun Pharma’s onco-dermatology portfolio, as it includes Unloxcyt (cosibelimab-ipdl), an FDA-approved anti-PD-L1 treatment indicated for advanced cutaneous squamous cell carcinoma (cSCC) (Ref 1) ❓ How will this acquisition position Sun Pharma in the immuno-oncology space? What is the indication expansion strategy for

March 1st Week, 2025 Regulatory Events 🎯 Bristol Myers Squibb’ nivolumab (anti-PD-1) + ipilimumab (anti-CTLA-4) has been approved by the EC as a first-line Tx for unresectable or advanced HCC. (Ref 1) ❓ How do the outcomes of nivolumab + ipilimumab compare against the previously approved Tx options for the first-line HCC? 🎯 Johnson & Johnson's amivantamab (EGFR x MET BsAb) + lazertinib (EGFR TKI) has been approved by the UK's MHRA for EGFR mutant, metastatic NSCLC. (Ref 2)

February 3rd Week, 2025 📝With the Ph3 CHECKMATE-816 trial meeting its key secondary endpoint of OS, BMS’ nivo + platinum-doublet CT became the first neoadjuvant-only Tx to significantly improve OS in resectable NSCLC patients. (Ref 1) ❓Will the positive OS data support BMS’ regimen in tackling the competitive threat from the perioperative chemo-IO regimens? 📝The US FDA will be assessing BI's NDA of zongertinib (irreversible ERBB2 TKI) for previously treated, HER2+ve, unres